The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Salkov V.N.

Scientific Center of Neurology

Khudoyerkov R.M.

Scientific Center of Neurology

Voronkov D.N.

Research Center of Neurology

Sobolev V.B.

Research Center of Neurology

Morphochemical study of alpha-synuclein, iron and iron-containing proteins in the substantia nigra of the brain in Parkinson’s disease

Authors:

Salkov V.N., Khudoyerkov R.M., Voronkov D.N., Sobolev V.B.

More about the authors

Read: 2398 times


To cite this article:

Salkov VN, Khudoyerkov RM, Voronkov DN, Sobolev VB. Morphochemical study of alpha-synuclein, iron and iron-containing proteins in the substantia nigra of the brain in Parkinson’s disease. Russian Journal of Archive of Pathology. 2022;84(2):13‑19. (In Russ.)
https://doi.org/10.17116/patol20228402113

Recommended articles:
The role of ferroptosis in reproduction. A modern view of the problem. Russian Journal of Human Reproduction. 2024;(5):35-45
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164

References:

  1. Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901-905.  https://doi.org/10.1007/s00702-017-1686-y
  2. Trist BG, Hare DJ, Double KL. A proposed mechanism for neurodegeneration in movement disorders characterized by metal dyshomeostasis and oxidative stress. Cell Chem Biol. 2018;25(7):807-816.  https://doi.org/10.1016/j.chembiol.2018.05.004
  3. Dusek P, Roos PM, Litwin T, Schneider SA, Flaten TP, Aaseth J. The neurotoxicity of iron, copper and manganese in Parkinson’s and Wilson’s diseases. J Trace Elem Med Biol. 2015;31:193-203.  https://doi.org/10/1016/j.jtemb.2014.05.007
  4. Gallegos S, Pacheco C, Peters C, Opazo CM, Aguayo LG. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson’s disease. Front Neurosci. 2015;(9):59.  https://doi.org/10.3389/fnins.2015.00059
  5. Walker DG, Lue LF, Adler CH, Shill H, Caviness J, Sabbagh M, Akiyama H, Serrano G, Sue L, Beach T. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol. 2013;240:190-204.  https://doi.org/10.1016/j.expneurol.2012.11.020
  6. Jellinger KA. Lewy body-related α-synucleinopathy in the aged human brain. J Neural Transm (Vienna). 2004;111(10-11):1219-1235. https://doi.org/10.1007/s00702-004-0138-7
  7. Jellinger KA. Neuropathology of sporadic Parkinson’s disease: Evaluation and changes of concepts. Mov Disord. 2011;27(1):8-30.  https://doi.org/10.1002/mds.23795
  8. Cersosimo MG, Perandones C, Micheli FE, Raina GB, Beron AM, Nasswetter G, Radrizzani M, Benarroch EE. Alpha-synuclein immunoreactivity in minor salivary gland biopsies in Parkinson’s disease patients. Mov Disord. 2011;26(1):188-190.  https://doi.org/10.1002/mds.23344
  9. Dickson DW. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2(8). Accessed October 12, 2021. https://doi.org/10.1101/cshperspect.a009258
  10. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA. 2004;101(26):9843-9848. https://doi.org/10.1073/pnas.0403495101
  11. Carboni E, Lingor P. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson’s disease. Metallomics. 2015;7:395-404.  https://doi.org/10.1039/c4mt00339j
  12. Reinert A, Morawski M, Seeger J, Arendt T, Reinert T. Iron concentrations in neurons and glial cells with estimates on ferritin concentrations. BMC Neurosci. 2019;20(1):25. Accessed October 12, 2021. https://doi.org/10.1186/s12868-019-0507-7
  13. Morawski M, Meinecke C, Reinert T, Dorffel AC, Riederer P, Arendt T, Butz T. Determination of trace elements in the human substantia nigra. Nucl Instrum Methods Phys Res Sect B. 2005;231:224-228.  https://doi.org/10.1016/j.nimb.2005.01.061
  14. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB. Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm Park Dis Dement Sect. 1990;2(4):327-340.  https://doi.org/10.1007/BF02252926
  15. Faucheux BA, Martin ME, Beaumont C, Hunot S, Hauw JJ, Agid Y, Hirsch EC. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson’s disease. J Neurochem. 2002;83(2):320-330.  https://doi.org/10.1046/j.1471-4159.2002.01118.x
  16. Korzhevskii DE, Sukhorukova EG, Grigor’ev IP. The distribution of iron in the substantia nigra in the human brain. S.S. Korsakov Journal of Neurology and Psychiatry=Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(6):77-80. (In Russ.). Accessed October 12, 2021. https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2013/6/031997-72982013614
  17. Genoud S, Roberts BR, Gunn AP, Halliday GM, Lewis SJG, Ball HJ, Hare DJ, Double KL. Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson’s disease brain. Metallomics. 2017;9(10):1447-1455. https://doi.org/10.1039/c7mt00244k
  18. Li K, Reichman H. Role of iron in neurodegenerative diseases. J Neural Transm. 2016;123(4):389-399.  https://doi.org/10.1007/s00702-016-1508-7
  19. Madhavi T. Inflammation in Parkinson’s disease: scientific and clinical aspects. Springer; 2014. Accessed October 12, 2021. https://doi.org/10.1007/978-3-319-08046-8
  20. Pchelina SN. Alpha-synuclein as a biomarker of Parkinson’s disease. Annals of Clinical and Experimental Neurology=Annaly Klinicheskoy I Experimental’noy Nevrologii. 2011;5(4):46-51. (In Russ.). Accessed October 12, 2021. https://annaly-nevrologii.com/wp-content/uploads/2016/09/Stranitsy-iz-Tom-5-4-2011-9.pdf
  21. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013;136(8):2419-2431. https://doi.org/10.1093/brain/awt192
  22. Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotox Res. 2003;5:35-44.  https://doi.org/10.1007/bf03033371
  23. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045-1060. https://doi.org/10.1016/s1474-4422(14)70117-6
  24. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease. J Neurochem. 2003;86(5):1142-1148. https://doi.org/10.1046/j.1471-4159.2003.01923.x

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.